Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04590781 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
A Phase 1 study, sponsored by Xencor.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04590781 is a Phase 1 study that was terminated before completion, run by Xencor. The registered enrollment target is 4 participants.
The verdict
NCT04590781, a Phase 1 study, was terminated before completion, sponsored by Xencor.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab in participants with metastatic Merkel cell (MCC) or locoregional MCC that has recurred after locoregional therapy with surgery and/or radiation therapy, and mAb18087 monotherapy in participants with extensive-stage small cell lung cancer (SCLC) that has progressed after standard therapies. This study was terminated by the sponsor. No participants enrolled in Part B.
Interventions
- BIOLOGICAL XmAb18087
- DRUG XmAb18087 ± Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04590781
The ClinicalTrials.gov registry entry for NCT04590781 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XmAb18087 is the first listed.
NCT04590781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04590781 about?
NCT04590781 is a clinical study titled "Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer". This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab in participants with metastatic Merkel cell (MCC) or locoregional MCC that has recurred after locoregional therapy wi...
What is the current status of trial NCT04590781?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-05-10. Estimated completion is 2022-03-24.
What interventions are being tested in trial NCT04590781?
The interventions under investigation include: XmAb18087 (BIOLOGICAL), XmAb18087 ± Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT04590781?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.